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Abstract  
Problem 
Fluctuating hormones regulate reproductive processes in the female genital tract.  
Consequent changes in the local immunological environment are likely to affect cellular 
interaction with infectious agents and the assessment of therapies that target mucosal 
infections.  
Method of study 
We compared Softcup and Weck-Cel sampling protocols and assessed the changes in the 
concentrations of 39 soluble proteins with menstrual cycle progression in the mucosal and 
peripheral compartments. 
Results 
We demonstrate that the mucosal immunological profile is distinct from serum with 
inflammatory and migratory signatures that are localised throughout the cycle. The analytes 
highlighted in the mucosal compartment were generally highest at the follicular phase with 
a tendency to fall as the cycle progressed through ovulation to the luteal phase. 
Conclusion 
Our results underscore the need to consider these localised cyclical differences in studies 
aimed at assessing the outcome of disease and the efficacy of mucosal vaccines and other 
therapies.  
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Introduction 
The female genital mucosa is home to cellular mediators of immunity such as Langerhans 
cells, CD4+ and CD8+ T cells, macrophages, dendritic cells, neutrophils, NK cells and B cells1. 
These cells mediate the innate and adaptive components of mucosal immunity often via the 
production of a plethora of chemokines, cytokines and other immunoproteins. CD4+ T cells 
expressing receptors like CD4 and CCR5 also constitute targets for infectious viral particles 
that traverse the epithelial barrier
2
. Layers of intact stratified squamous cells line the vagina 
and ectocervix whilst the single columnar epithelium maintains the integrity of the 
endometrium and endocervix2. Together these cells in the most exposed regions of the 
female genital tract provide a r asonable physical barrier to the entry of infectious 
pathogens like HIV and an additional secretory mucosal component containing amongst 
other things innate antimicrobial proteins like secretory leukocyte protease inhibitor (SLPI) 3 
and defensins
4
. 
Varying levels of endogenous female hormones like oestradiol and progesterone regulate 
the onset of ovulation, implantation, menstruation and other reproductive processes in the 
female genital tract5. These hormones are also known to induce changes in the appearance 
and function of mucosal tissue. For instance, over the course of the menstrual cycle 
hormonal fluctuations are believed to induce changes in the viscosity of the secretory 
component of the mucosal environment 6. The epithelial barrier is also reportedly affected 
by these changes as evidenced in the progesterone induced thinning observed in macaques 
7
. These changes have been shown to increase tissue susceptibility to Simian 
Immunodeficiency Virus (SIV) and are likely to affect HIV infection8, as well as the uptake 
and response to vaccines and topical microbicides.  Although absolute numbers of the 
Page 3 of 37
American Journal of Reproductive Immunology
American Journal of Reproductive Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Page 4 of 25 
 
immune cells are believed to fluctuate across the menstrual cycle 9, phenotypic changes and 
consequent variations in the levels of secreted chemokines, cytokines and immunoproteins 
in the periphery and in mucosal tissue  have not been fully elucidated. There is some 
evidence to show that the concentrations of immunoproteins in the mucosal compartment 
vary with the menstrual cycle 
10
. A recent study of cervicovaginal secretions obtained from 
Tanzanian women considered to be at high risk of HIV demonstrated increases in a number 
of mucosal analytes from pre- to post-ovulation phases of the menstrual cycle 11. Such 
significant variations in the levels of secreted immunoproteins over the menstrual cycle 
particularly if they are unique to the mucosal compartment are likely to affect the outcome 
and monitoring of therapies that target the mucosal compartment, thus making a case for 
the consideration of these differences in the evaluation of mucosal infections in general and 
in clinical studies aimed at designing or assessing interventions against HIV infection.  
Identifying the best sampling approach for evaluating mucosal responses to infection and 
therapy has been a priority, not only for HIV vaccine development, but also for the 
evaluation of microbicides 12, 13. Sample quality, ease of collection, processing and 
downstream analyses are common factors considered in selecting the appropriate 
approach. In this study we assessed the levels of 39 different soluble immunoproteins in 
secreted samples collected from the cervicovaginal compartment and compared them with 
those in the endocervix collected at a single time point corresponding to the follicular 
phase. In doing so we provide a direct comparison of two important mucosal sampling 
techniques. We also collected secretions from the cervicovaginal compartment at three 
distinct points that correspond with the follicular (proliferative), ovulatory and luteal 
(secretory) phases of the menstrual cycle and compared them with levels seen in the 
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peripheral compartment (serum) at the corresponding time points. Analytes assessed 
include cytokines, growth factors, chemokines, antimicrobial (including antiviral) proteins 
and immunoglobulins. We produced profiles of the immunological landscape across the 
menstrual cycle highlighting critical points that need to be considered in designing and 
assessing mucosal interventions against pathogens like HIV. 
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Results 
Characteristics of participants 
Although samples were collected from 31 women during the course of the study, 19 
participants were excluded on account of the participants not being available for sampling 
across all the time points (Figure 1), or not providing matching samples from all sampled 
compartments for comparison. Of the analysed participants, 4 were on combined oral 
contraception, one was on combined transdermal contraception whilst the rest of the 
analysed participants used barrier contraception (condoms). Participants were between the 
ages of 18 and 45 years with a median age of 27 years. 
Endocervical and cervicovaginal compartments display distinctive immunological analyte 
signatures in the follicular phase of the menstrual cycle 
Samples were collected from two compartments at visit 1 corresponding to days 5-10 of the 
menstrual cycle from study participants. We measured the concentrations of 39 analytes in 
the samples collected from the cervical os representing endocervical secretions or the upper 
vaginal region using Weck-Cel® spears or an Instead ® Softcup respectively. We found the 
analyte signatures to be similar overall (Figure 2A) with strong correlations (r = 0.96; p = 
0.0001) (Figure 2B). However, there were significant differences between the two 
compartments with regards to a few analytes. Although the average analyte concentrations 
were generally higher in the vaginal samples we observed significantly higher 
concentrations in 6/39 analytes (IL-6, p=0.0137; IFN-β, p=0.0005; SLPI, p=0.0005; MIP-3α, 
p=0.0010; P-Selectin, =0.0005; and G-CSF, p=0.0244) in the samples collected by direct 
adsorption from the cervical os with Weck-Cel® spears (Supplementary Table 1). Notably 
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there were no significant differences in the concentrations of mucosal antibodies (IgG1-4, 
IgA or IgM) recorded using both sampling techniques. Due to the observed correlation 
between the analyte signatures obtained using both techniques we opted to use Softcups in 
subsequent analysis as it was generally considered to be more acceptable and less invasive 
for study participants.  
Serum and cervicovaginal compartments display distinctive immunological analyte 
signatures across the menstrual cycle 
We compared analyte concentrations in the samples obtained from the upper vaginal 
region with those seen in the serum compartment and found the signature of each 
compartment to be distinct at visit 1 (Figure 3 and Table 1) . The differences in analyte 
concentrations in both compartments were significant for 29/39 analytes at visit 1 (Table 1). 
Of the 29 analytes that were found to be different 14 analytes (IL-6, IL-1α, IL-1β, IL-10, IL-2, 
β-defensin 3, Elafin, Hnp 1-3, IL-8, MIP-3α, IP-10, P-Selectin, G-CSF, and TGF-β) were higher 
in the mucosal compartment whilst 15 analytes (IL-12, IL-4, IL-15, IFN-β, SLPI, MCP-2, 
RANTES, L-Selectin, GM-CSF, IgG1, IgG2, IgG3, IgG4, IgA and IgM) were higher in the serum 
compartment. We observed similar differences in compartmental analyte signature was 
seen at visits 2 and 3 (Supplementary Figure 1 A-C). We then sought to determine how the 
unique signatures identified in the serum and vaginal compartments varied throughout the 
menstrual cycle. Overall we recorded more significant fluctuations in the concentrations of 
secreted analytes in the vaginal compartment across the menstrual cycle compared to the 
serum compartment where analyte concentrations appeared to vary less.   Specifically we 
recorded significant differences in 14/39 (IL-1β, IL-12, IL-16, IL-4, MCP-1, MIP-1β, RANTES, 
SDF-1β, L-Selectin, IgG1, IgG2, IgG3, IgG4, and IgM) analytes sampled in the cervicovaginal 
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compartment (Figure 4 and Supplementary Figure 2) and found that the concentrations of 
these analytes decreased across the menstrual cycle phases represented by the three time 
points that we sampled (i.e. decreased with progression from visits 1 to 3). The functional 
analyte groups highlighted by this trend included chemokines and antibody isotypes even 
though changes were recorded for analytes belonging to at least three other functional 
groups. Interestingly the concentrations of secreted analytes in the vagina appeared to be 
stable between the ovulation and luteal phases.  
We recorded significant differences in just 3/39 (SLPI, P-Selectin, and IL-7) analytes in the 
serum compartment (Figure 4 and Supplementary Figure 2) across the menstrual cycle with 
all but IL-7 increasing with cycle progression. Fluctuations in serum analyte concentrations 
across the cycle were significant for analytes belonging to three functional groups 
(Haemopoietic/growth factors, antimicrobial and cell homing). Immunoglobulin levels 
remained largely stable in the serum compartment throughout the cycle.  Notably there was 
no overlap between the analytes that were seen to vary across the menstrual cycle in the 
serum and vaginal compartments (Supplementary Figure 2).  
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Discussion 
Our study demonstrates that significant differences exist between the genital 
immunological secretome and the periphery throughout the menstrual cycle by producing 
profiles for 39 analytes that are relevant to the investigation of mucosal infections and the 
evaluation of vaccine responses 
14, 15
 at three key points of the menstrual cycle. This 
knowledge is critical because the mucosal environment remains a key route of acquisition 
and transmission for pathogens like HIV 2. The presence of strong local innate and adaptive 
mucosal immune responses is thought to be important for effective prevention and control 
of HIV infection 16, 17. It is also crucial to establish a baseline profile for these responses 
against which any intervention that targets infectious pathogens can be gauged.  
 
Our assessment of two mucosal sampling techniques show a direct correlation in the results 
obtained.  Absorbent sampling materials like Weck-Cel® or ophthalmic sponges/swabs are 
purportedly advantageous over cervicovaginal lavage (CVL) sampling methods that require 
sample dilution at the point of collection 14. However both methods are not necessarily 
optimal for volume standardisation and ease of sample collection. In studies comparing 
sampling of mucosal secretions using swabs or CVL, the latter resulted in higher 
concentrations of immunoproteins despite the extensive dilution of samples that occurred 
during CVL sample collection 
13
. Another study looking at cell recoveries for mucosal 
sampling techniques noted that the CVL approach enabled the recovery of the lowest 
amount of viable mononuclear leukocytes in comparison with collection with cytobrushes or 
biopsies 
18
. Softcups rank high in user acceptability 
12
 and have become increasingly popular 
due to the practical advantages of their use by study participants without the need for 
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clinical personnel, and possibility of obtaining cervicovaginal secretions as a concentrate 
without dilution leading to better detection of analytes in comparison with CVL 
14
. We 
sought to determine whether differences exist in the secreted analyte signatures observed 
using two sampling methodologies that have not been compared directly before. Whereas 
previous studies have highlighted the need to consider differences that may arise as a result 
of methodology or the location of sampling in the genital tract 13, 14, 19 we found strong 
correlations between the secreted analyte signatures observed in samples collected and 
eluted from   Weck-Cel®  sponges and those collected using Softcups. However analyte 
concentrations were distinctly higher in the samples collected using the Softcups. The latter 
observation is in agreement with a previous study comparing Softcups with CVL sampling 14. 
This combined with the higher acceptability of self-sampling provided the rationale for using 
Softcups for the rest of this study. The notable exceptions to this observation (IL-6, IFN-β, 
SLPI, MIP-3α, P-Selectin and G-CSF) may reflect some effect of the different sampling 
methodology, or actual differences in the quantities of secreted analytes at various sites in 
genital tract that need to be taken into account when either technique is being utilised. 
Differences in administration of the sampling techniques used in this study mean that the 
Weck-Cel® sponges would have absorbed secretions around the cervical os, whilst the 
insertion of the Softcup in the vaginal would facilitate the collection of samples from several 
regions of the cervicovaginal tract.  
 
We demonstrate fluctuations in mucosal analytes (IL-1β, IL-12, IL-16, IL-4, MCP-1, MIP-1β, 
RANTES, SDF-1β and L-Selectin) across the time points that were examined in this study. 
Evaluation of the functional associations of the analytes that fluctuated significantly across 
the menstrual cycle in the reproductive compartment revealed the prominence of cellular 
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chemoattractants and proteins associated with the migration of hematopoietic cells. These 
factors have been shown to target a range of immune cell types including CD4
+
 T cells, NK 
cells, B cells and monocytes 20-23. Changes in mucosal immunoglobulins and in proteins 
associated with the modulation of the inflammatory response (IL-1β) 24 and the release of 
inflammatory cytokines (IL-12) 
25, 26
 were also demonstrated. The analytes highlighted by 
this study in the mucosal compartment were generally highest at the follicular phase (visit 1) 
with a tendency to fall as the cycle progressed through ovulation (visit 2) to the luteal phase 
(visit 3). A study by Francis et al that examined the changes in analyte concentrations pre- 
and post-ovulation also revealed a menstrual cycle phase signature in which the 
concentrations of chemoattractants like MCP-1 and SDF-1β decreased as the cycle 
progressed beyond ovulation whilst IL-18, IL-10, IL-17 and TGF-β increased. Consistent with 
our data and those of others 27, 28, they also saw a fall in the concentration of mucosal 
immunoglobulins 11  
 
Endometrial function and the menstrual cycle is tightly regulated by hormones such as 
oestrogen and progesterone to ensure the sustenance of progeny. Progesterone increases 
soon after ovulation resulting in the beginning of what is generally known as the secretory 
phase of the menstrual cycle where it prepares for the reception of a fertilised egg. This 
release peaks around day 22 after which progesterone withdrawal occurs as a result of the 
disintegration of the corpus luteum5. Mouse experiments and in vitro studies using human 
cells show that the withdrawal of the anti-inflammatory effect of progesterone in the 
follicular phase results in an increase in inflammatory analytes under the direct control of 
NF-κB 29 30, 31 and a steady rise in the population of mucosal leucocyte 32 and antigen 
presenting cells 33. In addition to higher levels of inflammatory markers we found evidence 
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of high levels of analytes that direct the influx of immune cells in mucosal samples obtained 
in the follicular phase (visit 1).   This very specific signature appeared to be localised and 
conspicuously absent in the peripheral compartment where we recorded significant changes 
for just three analytes (IL-7, P-Selectin and SLPI).  Although distinct from the mucosal 
compartment, the changes seen in the periphery could be significant in so much as they 
indicate the initiation of immune cell homeostasis, migration to mucosal sites and priming 
for any infection as a result of rising levels of inflammation. 34 35, 36. The inflammatory and 
migratory signature seen in the mucosal compartment was significantly reduced by visit 2 
which coincides with ovulation and rising levels of progesterone in the mucosal 
compartment. 
 
These findings can inform our understanding of mucosal infections and the approach to 
evaluating interventions. For example, a localised surge in mucosal inflammation and 
migratory signals in the follicular phase may create an enabling environment for HIV entry 
into susceptible cells that have migrated into the mucosal environment 2, 37 and found their 
way into its secretions 
18
. A number of the analytes that were highlighted in our results have 
been implicated in the provision of migratory stimulus to antigen presenting cells 38, 
including lymphocytes which are capable of viral  uptake and  the presentation of HIV 
antigens 
2
. An influx of antigen presenting cells (APCs) in response to these migratory and 
inflammatory or danger signals in the late luteal and follicular33 phase may result in the 
uptake of virus upon exposure and the subsequent migration of APCs to the draining lymph 
nodes where further dissemination can occur 
2
. Targeting of mucosal vaccines to the late 
luteal or follicular phase for instance may enhance their uptake or efficacy.  
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In this study we have measured 39 analytes to provide a picture of how they vary in the 
mucosal versus peripheral compartment and across the menstrual cycle. In doing so we also 
provide a comparison of key mucosal sampling methods to inform therapeutic research.  
The limitations of this study includes the small sample size and the absence of a direct 
quantification of hormone levels in study participants. However we reasoned that samples 
collected at visits 1 and 3 in normal cycling women would enable us to compare the 
immunological profiles at the peak of oestrogen and progesterone release, respectively. In 
addition we have not adjusted our findings to reflect any difference that may arise from 
reported behaviours described in the methods section such as the use of oral contraception, 
or unreported/undiagnosed infections in volunteers. It is also worth pointing out that four 
of the participants in this study were on oral combined contraception whilst one was on 
combined transdermal contraception even though they all had regular withdrawal bleeding.  
 
Nevertheless our data highlight the need to standardise the timing of mucosal sampling in 
clinical studies.  One approach could be to ensure that sampling in all study participants 
occurs within a similar period of the menstrual cycle to ensure that the differences in local 
cyclical effects are minimised. A similar advantage would be applicable if the administration 
and assessment of therapies are designed to fall within similar periods within the menstrual 
cycle. As an example, the period defined by visits 2-3 of our study showed the least amount 
variation in analyte concentrations (Figure 4), presenting a relatively long window to 
accommodate the challenges of scheduling of volunteer visits for clinical studies.   Where 
practically possible, studies could also be designed to target this period, or other periods of 
the cycle.  
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There is currently a need to design and evaluate vaccines that are capable of eliciting 
protective mucosal immunological responses that can prevent HIV acquisition and 
transmission39-41, particularly in women2 who have been reported to be more susceptible to 
infection compared to age-matched males 42. Indeed a number of studies have evaluated 
aspects of this approach such as the linkage between the nasal and genital mucosal 
compartments43, and the quality of the responses that are elicited by various antigens and 
delivery methods44, 45. None of these studies have taken into account the role that the 
unique and dynamic cervicovaginal immunological landscape might have on the outcome of 
vaccine regimens. Our data demonstrates the need to fully consider this in the design and 
execution of future vaccine studies.  
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Methods 
Study design and ethical approval 
The CASHIR (Characterisation of the activity and stability of anti-HIV-1 agents in the 
presence of female genital secretions and establishing methods to measure immune 
response) study was initiated to help in the development of novel agents against mucosal 
infections such as HIV. Its main aim was to provide some clarity on reliable methods used to 
measure immune responses in the female genital tract. As such it was designed as a 
longitudinal prospective cohort study to enable the standardization and comparison of 
methods and sampling approaches. We set out to explore the measurement of cytokine, 
chemokine and antibody responses in cervical/vaginal secretions and serum, taking into 
cognisance the effect of the menstrual cycle on these factors. Samples were collected at The 
Vaccine Institute, St George’s University of London. All volunteers gave full informed and 
written consent. All relevant approvals were in place and the study was conducted in 
accordance with the relevant Clinical Regulations and guidelines on Good Clinical Practice.  
 
Subjects and sample collection protocol 
Screening was focused on healthy female volunteers aged 18-45 years who were HIV 
negative, recruited through the use of staff and student mail shots and through the 
placement of posters within the campuses of St George’s University of London and St 
George’s Foundation Trust Hospital notice boards. Volunteers were questioned by a doctor 
or trained research nurse for any history of sexually transmitted infections like HIV and 
administered with a pregnancy test.  Exclusion criteria were set out as a) Inability to consent 
b) women who were actively menstruating c) women who have had unprotected (condoms) 
sexual intercourse 24 hours prior to sample collection, d) women who had intrauterine 
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contraceptive device in situ e) ability to communicate effectively with clinical team.  In 
addition, participants who developed bacterial vaginosis, thrush or went on antibiotics were 
made to wait until the next cycle for collection with repeats to first sample collection 
initiated where necessary. Screened women were eligible to participate if they had regular 
menstrual cycles of 28-day duration on average. Samples were collected during three 
scheduled visits coinciding with days 5-10 (end of menstruation; follicular phase), days 14-
16 (ovulation), and days 19-24 (luteal phase) of the menstrual cycle. Day 1 coincided with 
the first day of their menses.  
 
Serum was collected for antibody and analyte screening at all three visits. Briefly, 10 ml of 
peripheral blood was centrifuged in sterile collection tubes for ten minutes at 400 x g to 
obtain serum. Serum samples were immediately stored at ≤ -15 ⁰C in 500 µl aliquots. 
Cervicovaginal secretions were collected by study participants at all three visits using 
INSTEAD Softcup ® (Evofem Inc). The Softcup was self-inserted into the upper vaginal region 
and left in situ for one hour before being placed in a sterile 50 ml collection container 
(Beckton Dickinson, UK) for immediate storage at -80 ⁰C prior to analysis. For analysis, 
volumes of samples were measured using a positive displacement pipette and diluted in 
extraction buffer [250 mM NaCl, 1× protease inhibitor cocktail set 1 (Calbiochem) in 
phosphate buffered saline (1XDPBS, Gibco)] prior measuring analyte concentrations by 
Luminex. Additional endocervical secretion samples were collected from volunteers at visit 
1 (corresponding to days 5-10 of the menstrual cycle and at the same time that 
corresponding CVS was collected) under speculum examination using a Weck-Cel® 
ophthalmic sponge. Two sponges were placed in the cervical os for 1 minute each to 
passively absorb cervical secretions. After removal the Weck-Cels® were immediately 
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transferred into Costar® Spin-X® polypropylene microcentrifuge filter tubes (Corning Inc) 
containing extraction buffer and stored at -80 until analysis. 
 
Processing of samples for Immunological assays 
Prior to immunological analysis serum sample aliquots were heat inactivated at 56 ⁰C with 
slow mixing for 35 minutes. Softcups containing secretions in 50 ml collection tubes were 
removed from -80 ⁰C, allowed to thaw on ice, and centrifuged at 400 x g for 15 minutes at 4 
⁰C.  An equal volume of extraction buffer was then added to the secretion samples (after 
removal of the cup) with mixing. Processed aliquots were then used in immunological assays 
or frozen at -80 ⁰C. Similarly Spin–X tubes containing Weck-Cel® spears (sponges) were 
thawed on ice, centrifuged at 13,000 rpm in a micro-centrifuge at 4 ⁰C. 300µl extraction 
buffer was added to the top chamber of the Spin–X tube containing the spears centrifuged 
again for an additional 15 minutes at 13,000rpm and 4 ⁰C to further extract any residual 
secretions. Sponges were removed and eluates used in assays or aliquoted for storage at -
80⁰C. 
 
Measurement of Immunological proteins 
Thirty-three soluble immune proteins were quantified in all processed samples using an in-
house Luminex assay comprising of four panels. The proteins analysed were as follows; 
Panel 1- IL-7, IL-6, G-CSF, MIP-3α, IL-8, MCP-1. Panel 2- GM-CSF, IP-10, IL-12, MIG, IL-16, IL-
2, RANTES, MCP-2, IL-4, MIP-1β, IL-1α, SDF-1, IFN-γ, IFN-β, TGFβ, IL-1β, IL-15, TNFα. Panel 3- 
β3-Defensin, IL-17, IL-10, β4-Defensin, L-Selectin. Panel 4- SLPI, Elafin, Hnp 1-3 and P-
Selectin. Additionally, six immunoglobulin (Ig) isotypes (IgG1, IgG2, IgG3, IgG4, IgA, IgM) 
were measured using a Bio-Plex Pro Human Isotyping 6-plex panel kit from Bio-rad 
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Laboratories, In all cases, a set of standard curves were run on each plate. UK according the 
manufacturer’s instructions. Analytes were quantified using Bio-Plex® 100 Luminex analyzer 
(Bio-rad Laboratories). Data was collected for three replicates per sample using Bio-Plex 
Manager Software version 6. A five parameter logistic regression formula was used to derive 
sample concentrations from the standard curves. Analytes below the lower limit of 
detection were assigned a concentration of half the lower limit of quantification (LLOQ).  
 
Statistical analysis 
Data was characterised using a range of statistical methods. We did not assume a normal 
distribution for analyte concentrations in our population. The comparison of analyte 
concentrations in paired samples collected from various compartments was performed 
using the non-parametric Wilcoxon matched-pairs signed ranked test. The same method 
was applied to the evaluation of analyte fluctuations in each compartment over the 
menstrual cycle. Spearman correlation was used to calculate the relationships between 
analyte sampling techniques and compartmental secretions. p-values were generally 
considered not significant at ≥0.05. All statistical analyses were performed and graphs 
drawn using Graphpad Prism 6 Software.  
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Table 1: Median analyte concentrations in the peripheral (serum) and mucosal 
(cervicovaginal) compartments in the follicular phase of the menstrual cycle 
Functional 
classification Analyte Unit 
Cervicovaginal region 
(Softcup) Serum p value 
   median (range) median (range)  
Pro-inflammatory 
IL-6 pg/ml 351.7 (2.0-2300) 17.3 (2.0-36.7) 0.0098 
IL-1α pg/ml 1023.3 (556.7-11943.3) 4.0 (1.0-10.3) 0.0010 
IL-1ß pg/ml 323.3 (123.3-3300) 30.0 (4.0-43.3) 0.0010 
IL-12 pg/ml 4.7 (2.0-20) 36.7 (19.3-60.0) 0.0010 
IL-16 pg/ml 56.7 (17-10683.3) 205.0 (205.0-231.0) 0.3496 
IL-17 pg/ml 35.0 (35.0-196.7) 164.0 (17.0-164.0) 0.5449 
TNF-α pg/ml 2.0 (2.0-73.3) 17.3 (2.0-26.7) 0.0996 
Anti-inflammatory IL-10 pg/ml 133.0 (6.0-244.0) 66.0 (22.0-98.0) 0.0371 
Adaptive 
IL-2 pg/ml 146.7 (20.0-356.7) 22.0 (22.0-151.33) 0.0049 
IL-4 pg/ml 44.0 (20.0-280.0) 515.7 (57.0-913.3) 0.0010 
IL-15 pg/ml 1.0 (1.0-1.0) 4.0 (1.0-10.7) 0.0313 
IFN-γ pg/ml 19.0 (17.0-110.0) 18.7 (3.0-86.7) 0.3096 
Antimicrobial 
IFN-ß pg/ml 1.0 (0.3-10.0) 100.7 (16.0-233.3) 0.0010 
ß-defensin 3 ng/ml 18.8 (8.0-48.8) 3.8 (1.0-5.3) 0.0020 
ß-defensin 4 pg/ml 2.0 (2.0-603.3) 3.0 (2.0-110.0) 0.6250 
SLPI ng/ml 10.6 (4.5-18.7) 33.9 (23.7-48.7) 0.0010 
Elafin ng/ml 4473.5 (27.5-4906.2) 6.5 (2.1-10.5) 0.0010 
Hnp-1-3 µg/ml 21.4 (8.8-250.0) 0.2 (0.007-1.3) 0.0010 
Chemokine 
IL-8 pg/ml 30120.0 (10846.6-76113.3) 2.5 (2.0-2.5) 0.0020 
MCP-1 pg/ml 170.0 (4.7-2656.7) 260.0 (156.7-430.0) 0.7646 
MCP-2 pg/ml 2.0 (2.0-36.7) 110.0 (73.3-120.0) 0.0010 
MIP-1ß pg/ml 20.0 (2.0-706.7) 53.3 (43.3-93.3) 0.4502 
MIP-3α pg/ml 900.0 (126.7-7626.7) 36.5 (36.5-39.5) 0.0010 
RANTES pg/ml 10.0 (1.0-116.7) 32826.7 (11133.3-47480.0) 0.0010 
IP10 pg/ml 606.7 (290.0-4700.0) 113.3 (60.0-226.7) 0.0010 
SDF-1ß pg/ml 43.3 (33.3-980.0)  78.7 (13.0-250.0) 0.7646 
MIG pg/ml 120.0 (50.7-826.7) 166.7 (123.3-193.3) 0.8948 
Cell homing 
L-Selectin ng/ml 0.6 (0.1-11.2) 103.8 (73.4-136.0) 0.0020 
P-Selectin ng/ml 189.8 (124.1-436.9) 111.5 (50.3-268.4) 0.0010 
Hematopoietic/ 
Growth factor 
IL-7 pg/ml 9.0 (7.0-93.3) 13.5 (4.0-55.7) 0.7480 
GCSF pg/ml 2008.3 (506.7-7650.0) 24.0 (1.5-107.2) 0.0020 
GM-CSF pg/ml 7.3 (2.0-26.7) 86.7 (48.7-103.3) 0.0010 
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TGF-ß pg/ml 313.3 (33.3-6130.0) 126.7 (32.7-183.3) 0.0146 
Antibody 
IgG1 µg/ml 46.8 (14.1-119) 10138.0 (5491.9-14248.4) 0.0039 
IgG2 µg/ml 80.1 (38.9-214.4) 11272 (6433.5-16170.0) 0.0039 
IgG3 µg/ml 1.7 (0.2-10.9) 646.4 (266.6-1399.5) 0.0039 
IgG4 µg/ml 1.2 (0.0-2.9) 332.6 (6-855.2) 0.0078 
IgA µg/ml 29.6 (8.2-113.3) 1427.7 (628.4-2674.6) 0.0039 
IgM µg/ml 1.7 (0.5-91.6) 2108.2 (1743.4-2960.6) 0.0039 
Wilcoxon matched-pairs signed rank Test applied to values recorded for study subjects at visit 1 with p values <0.05 
considered to be significant 
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Figure 1: Illustration of the timeline for study visits with a list of the localised analyte changes occurring in 
the mucosal compartment. Phases of the menstrual cycle were specified for volunteers as the number of 
days since their last menstrual period where day 1 coincided with the first day of their menses. Samples 
were collected during three scheduled visits coinciding with days 5-10 (end of menstruation; follicular 
phase), days 14-16 (ovulation), and days 19-24 (luteal phase). More analyte fluctuations were recorded in 
study subjects over the time points that were investigated in the mucosal compartment compared to the 
serum compartment.  
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Figure 2A-B: Analysis of the secreted immunoproteome in the female genital tract. A) Sampling with Softcup 
and Weck Cel sampling techniques reveal similar analyte signatures at visit 1 (corresponding to days 5-10 of 
the menstrual cycle) in the vaginal and cervical os of 12 healthy women aged 18-45 years. Points represent 
mean analyte concentration (pg/ml) of three experimental replicates. B) Comparison of 39 analyte 
concentrations (activity; ng/ml) in matched vaginal and cervical os samples collected from 12 women by 
Spearman rank correlation. Concentrations shown as Log 10 values in ng/ml. p= <0.0001. 95% confidence 
interval = 0.9184-0.9781.  
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Figure 4: More analyte fluctuations observed across the menstrual cycle in the vaginal compartment 
compared to the serum compartment. Vertical lines represent the points where no change in analyte 
concentration occurred. Horizontal lines indicate the points where significance is achieved. p-values < 0.05 
were considered to be significant.  
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Supplementary material 
 
Table 1: Median analyte concentrations in the mucosal sub-compartments in the follicular 
phase of the menstrual cycle 
Functional 
classification Analyte Unit 
Cervicovaginal 
region (Softcup) 
Endocervical region 
(Weck Cel) p value 
   median (range) median (range)  
Pro-inflammatory 
IL-6 pg/ml 326.7 (2.0-2300) 713.3 (33.3-2490.0) 0.0137 
IL-1α pg/ml 993.3 (556.7-11943.3) 98.3 (40.0-640.0) 0.0005 
IL-1ß pg/ml 313.3 (40.0-3300.0) 83.3 (16.7-473.3) 0.0049 
IL-12 pg/ml 4.7 (2.0-20.0) 10.5 (9.0-12.0) 0.0586 
IL-16 pg/ml 48.3 (17.0-10683.3) 2050 (73.3-2050.0) 0.1514 
IL-17 pg/ml 35.0 (35.0-290.0) 25.0 (5.3-30.0) 0.0010 
TNF-α pg/ml 2.0 (2.0-73.3) 2.0 (1.3-7.3) 0.6250 
Anti-inflammatory IL-10 pg/ml 138.7 (6.0-244.0) 19.0 (4.0-21.3) 0.0049 
Adaptive 
IL-2 pg/ml 180.0 (20.0-356.7) 36.7 (3.7-80.0) 0.0010 
IL-4 pg/ml 41.2 (10.0-280.0) 117.0 (80.7-186.7) 0.2734 
IL-15 pg/ml 1.0 (1.0-1.0) 1.0 (0.7-1.0) >0.9999 
IFN-γ pg/ml 19.0 (17.0-110.0) 19.0 (14.0-50.0) 0.4648 
Antimicrobial 
IFN-ß pg/ml 2.2 (0.3-10.0) 19.0 (14.0-50.0) 0.0005 
ß-defensin 3 ng/ml 20.3 (8.0-48.8) 1.1 (0.3-8.6) 0.0010 
ß-defensin 4 pg/ml 2.0 (2.0-603.3) 2.0 (2.0-10.0) >0.9999 
SLPI ng/ml 10.7 (4.5-18.7) 68.0 (33.9-151.8) 0.0005 
Elafin ng/ml 4424.9 (27.5-4906.2) 445.0 (146.2-1351.8) 0.0010 
Hnp-1-3 µg/ml 22.3 (8.8-250.0) 28.5 (40.72-285.6) 0.8501 
Chemokine 
IL-8 ng/ml 28.1 (10.8-76.1) 10.5 (2.0-35.1) 0.0029 
MCP-1 pg/ml 108.3 (4.6-2656.7) 178.3 (26.7-1053.3) 0.9697 
MCP-2 pg/ml 2.0 (2.0-36.7) 7.3 (4.7-10.0) 0.3145 
MIP-1ß pg/ml 11.0 (2.0-706.7) 225 (10.0-2166.7) 0.1763 
MIP-3α pg/ml 861.7 (126.7-7626.7) 9938.335 (97.0-20553.3) 0.0010 
RANTES pg/ml 10.0 (1.0-116.7) 15 (0.0-73.3) 0.4004 
IP10 pg/ml 766.7 (290.0-4700.0) 321.7 (33.3-1453.3) 0.0005 
SDF-1ß pg/ml 48.3 (33.3-980.0) 156.7 (10.7-920.0) 0.5195 
MIG pg/ml 125.0 (50.7-826.7) 27 (10.7-920.0) 0.0010 
Cell homing 
L-Selectin ng/ml 0.5 (0.1-11.2) 0.8 (0.1-7.7) 0.8984 
P-Selectin ng/ml 200.7 (124.0-436.9) 543.9 (201.2-1112.6) 0.0005 
Hematopoietic/ 
Growth factor 
IL-7 pg/ml 9.0 (7.0-93.3) 20.0 (4.7-33.3) 0.8945 
GCSF ng/ml 1.9 (0.5-7.7) 4.2 (0.1-14.1) 0.0244 
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GM-CSF pg/ml 7.3 (2.0-26.7) 6.0 (5.0-13.3) >0.9999 
TGF-ß pg/ml 331.7 (33.3-6130.0) 34 (2.0-56.7) 0.0010 
Antibody 
IgG1 µg/ml 46.8 (14.0-119.5) 63.9 (12.9-623.1) 0.0977 
IgG2 µg/ml 80.1 (38.9-214.4) 69.4 (47.8-274.6) 0.9102 
IgG3 µg/ml 1.8 (0.2-10.9) 1.6 (0.1-30.2) 0.2031 
IgG4 µg/ml 1.2 (0.0-2.8) 2.1 (0.0-3.5) 0.2031 
IgA µg/ml 29.6 (8.1-113.3) 57.2 (5.1-137.3) 0.5703 
IgM µg/ml 1.7 (0.5-91.6) 3.2 (0.3-78.3) 0.4961 
Wilcoxon matched-pairs signed rank Test applied to values recorded for study subjects at visit 1 with 
p values <0.05 considered to be significant  
Page 33 of 37
American Journal of Reproductive Immunology
American Journal of Reproductive Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Page 3 of 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 34 of 37
American Journal of Reproductive Immunology
American Journal of Reproductive Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Page 4 of 5 
 
 
Page 35 of 37
American Journal of Reproductive Immunology
American Journal of Reproductive Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Page 5 of 5 
 
 
Supplementary Figure 1 A-C: Analyte signatures differ between peripheral (serum) and 
mucosal (Softcup) compartments across the menstrual cycle. Floating bars show maximum 
and minimum values recorded for 39 analytes in both compartments with a line at the 
median for samples collected from study participants at A) visit 1; days 5-10, B) visit 2; days 
14-16, and C) visit 3; days 19-24. Data shown for three experimental replicates. 
 
Supplementary Figure 2: More analyte fluctuations were observed in samples collected from 
the vaginal compartment (●) across the menstrual cycle compared to matched samples 
collected from the serum compartment (●). Scatter dots are representative of three 
experimental replicates with bars and lines showing median values and range. p-values 
<0.05 were considered to be significant. 
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